City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly-impossible-to-treat cancer into a disease that can be corralled into remission.
City of Hope to further its extensive liver cancer research through a $2 million gift from Samson Holding Ltd., Samuel Kuo and Grace LiuApril 5, 2019
City of Hope has received a $2 million gift from leading furniture wholesaler Samson Holding Ltd., Samuel Kuo and Grace Liu to advance surgical oncologist Yuman Fong, M.D.’s pioneering liver cancer research.
Jianjun Chen, Ph.D., has been named the Simms/Mann Family Foundation Chair in Systems Biology at City of Hope in recognition of his leading-edge research that is helping to build the foundation of personalized, gene-based medicine.
Triplex meets primary endpoint in phase 2 clinical trial, reduces rate of cytomegalovirus (CMV) complications in transplant recipients by 50 percentMarch 26, 2019
First prophylactic vaccine to demonstrate proof of concept for CMV control independent of human leukocyte antigen (HLA) status in stem cell transplant recipients.
Akrevia Therapeutics Licenses Exclusive Rights from City of Hope to Expand Development Pipeline of Potent, Tumor Targeted ImmunotherapiesMarch 26, 2019
Akrevia Therapeutics, a privately held biopharmaceutical company focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics, and City of Hope, an independent research and treatment center for cancer, diabetes and other life-threatening diseases, have entered into an exclusive licensing agreement that will allow Akrevia to utilize innovative technology to engineer potent immune-activating cytokines that can be selectively activated in the tumor microenvironment.
The hemoglobin A1c blood test is widely used to diagnose type 1 and type 2 diabetes but it is actually unable to detect the disease in most patients, according to a new study presented Saturday, March 23, at a news conference at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans, La.
City of Hope will showcase ongoing studies and data on chimeric antigen receptor (CAR) T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research (AACR) annual meeting from March 29 through April 3 in Atlanta.
City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma (CTCL).
ConsumerMedical, the medical ally for participants to make informed medical choices, today announced the addition of City of Hope, a world-renowned independent cancer research and treatment center, to its world-class network of remote expert opinion providers for cancer.
A City of Hope scientist and his colleagues have developed a user-friendly approach to creating “theranostics” – therapy combined with diagnostics – that target specific tumors and diseases.